Gliogene: Brain Tumor Linkage Study
2 other identifiers
observational
17,080
6 countries
15
Brief Summary
The goal of this research study is to investigate the role of genes that may point to a higher risk of developing a glioma. Researchers will use new gene mapping techniques to study how high-risk factors are passed on through a family's genes and increase the risk of developing gliomas. Objectives: We propose an international multi-center, multidisciplinary study consortium, GLIOGENE, to identify susceptibility genes in high-risk familial brain tumor pedigrees using the most sophisticated genetic analysis methods available. To address our hypothesis, we propose the following specific aims: Aim 1: Establish a cohort of 400 high-risk pedigrees for genetic linkage analysis. To date, we have identified and collected biologic samples from 20 high-risk families that have met our criteria of 2 or more relatives diagnosed with a brain tumor. From the 15 centers in the United States and Europe, we will screen and obtain epidemiologic data from approximately 17,080 gliomas cases to identify a target of 400 families for genetic analysis. We will establish a cohort of the first and second-degree relatives from these glioma cases to obtain new knowledge about how cancer aggregates in glioma families. We will also acquire biospecimens (blood and tumor tissue), and risk factor data from relevant family members. Aim 2: Identify candidate regions linked to familial brain tumors. To strengthen evidence of linkage to regions found in our preliminary analysis and to identify additional regions linked to brain tumors, we will genotype informative glioma pedigrees identified in aim 1 using Affymetrix 10K GeneChip with markers spaced throughout the genome, and conduct a genome-wide multipoint linkage scan with these markers. Aim 3: Fine map the regions established in Aim 2 by genotyping selected SNPs from genome databases. We will attempt to further refine the regions identified in Aim 2 to less than 1cM by using approximately 1,500 - 2,000 carefully selected SNPs. The prioritization of regions will be based on a combination of the strength of evidence for linkage from families of various ethnic backgrounds and the presence of obvious candidate genes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2004
Longer than P75 for all trials
15 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 12, 2004
CompletedFirst Submitted
Initial submission to the registry
January 3, 2007
CompletedFirst Posted
Study publicly available on registry
January 5, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2022
CompletedDecember 31, 2020
December 1, 2020
18.6 years
January 3, 2007
December 29, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Patients' Susceptibility Genes in High-risk Familial Brain Tumor Pedigrees
13 Years (Collection of blood tests and survey/interviews)
Study Arms (1)
GLIOGENE
International Multi-Center, Multidisciplinary Study Consortium
Interventions
Questionnaire, 30-40 minutes, about gliomas and its risk factors (such as environmental and genetic information).
Eligibility Criteria
Study participants with a glioma or a family member of someone with a glioma.
You may qualify if:
- \) An affected or unaffected member of a family that has two or more reported gliomas (ICD9 codes 191.0-191.9) in the family.
You may not qualify if:
- N/A
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- M.D. Anderson Cancer Centerlead
- National Cancer Institute (NCI)collaborator
Study Sites (15)
University of California Medical Center, San Francisco
San Francisco, California, 94143, United States
Moffitt Cancer Center
Tampa, Florida, 33612, United States
University of Illinois Medical Center, Chicago
Chicago, Illinois, 60612, United States
Evanston NW Healthcare
Evanston, Illinois, 60201, United States
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
Baylor College of Medicine
Houston, Texas, 77030, United States
Texas Children's Hospital
Houston, Texas, 77030, United States
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Institute of Cancer Epidemiology
Copenhagen, Denmark
Tampere University Hospital
Tampere, Finland
The Danek Gertner Institute
Tel Litwinsky, Israel
Umeå University Hospital
Umeå, Sweden
Institute of Cancer Research
London, United Kingdom
Related Links
Biospecimen
About 3 tablespoons of blood will be drawn and if unable to donate blood, researchers will collect a saliva sample.
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sanjay Shete, PHD
M.D. Anderson Cancer Center
Study Design
- Study Type
- observational
- Observational Model
- FAMILY BASED
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 3, 2007
First Posted
January 5, 2007
Study Start
February 12, 2004
Primary Completion
September 1, 2022
Study Completion
September 1, 2022
Last Updated
December 31, 2020
Record last verified: 2020-12